CVM - CEL-SCI Corp. Company Total Debt

CVM (CEL-SCI Corp) - company brandmark

The development of CEL-SCI Corporation (CVM) is based on the prospects of Multikine and compliance with GMP standards. The total debt burden reflects the credit load dynamics, where the current figure stands at 0.01. The absence of a stable cash flow and reliance on external capital create a certain inertia. Simultaneously, the company is implementing energy-efficient solutions and chemical recycling to comply with environmental regulations.

CEL-SCI Corp. - CVM Company Debts (period 07/04/2022 - 10/28/2026)

CEL-SCI Corporation (CVM) - metric breakdowns and financial figures

- price and consensus price forecast:
Share Price cel-sci.com|CVM - Analyst Consensus Forecast
- market capitalization data:
Market Valuation CEL-SCI Corp|CVM - Enterprise Value
- book capitalization data:
Net Asset Value per Share CEL-SCI|CVM - Company Book Value|Market Value to Book Value cel-sci.com|CVM - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio CEL-SCI Corporation|CVM - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio cel-sci.com|CVM - Company Total Debt|Debts to Book Capitalization CEL-SCI Corp|CVM - Company Long-Term Debt|Company Short-Term Loans and Borrowings CEL-SCI
General company analysis:CEL-SCI Corp. CVM
Signature product of CEL-SCI

This indicator tracks the total volume of borrowed capital, allowing for the differentiation of strategic development from insolvency risks through an analysis of the liability structure. The dynamics of total credit obligations help investors assess how effectively CEL-SCI Corporation (CVM) finances the costly R&D processes for the Multikine system, balancing a technological breakthrough in immunotherapy against its debt load.

Main competitors

Company Aggregate Debt BeiGene Oncology (ONC)|Halozyme Therapeutics - Company Aggregate Debts|Company Total Debt revmed.com RVMD|AAPG (Ascentage Pharma) - Company Aggregate Debts|CGON: Company Cumulative Debt|Company Debts UroGen URGN|Aggregate Debt Obligations Bicara Corp|PSNL - Company Total Debt|Aggregate Debt Obligations erasca.com|Company Aggregate Debts DCTH (Delcath Systems)|Company Total Debt Y-mAbs Therapeutics Inc YMAB|Company Total Debt AURA (Aura Bio)|Candel Therapeutics Inc. - Company Aggregate Debts|Company Debts Accuray Incorporated (ARAY)|SLS - Aggregate Debt Obligations|Company Aggregate Debts ACTU|Citius Oncology Inc. (CTOR) - Company Cumulative Debt|Company Aggregate Debts HURA|Company Total Debt Protara Tx|Fate Therapeutics, Inc. - Company Aggregate Debts|Company Cumulative Debt WHWK (aadibio.com)|Company Debts TScan Therapeutics, Inc. TCRX|CSBR - Company Debts|Company Total Debt XBIT|OSTX: Company Total Indebtedness|Radiopharm Theranostics - Company Debts|Artiva Biotherapeutics (ARTV) - Company Total Debt Obligations|Company Aggregate Debts ANL|Company Total Debt Veru Inc|TPST (Tempest Tx) - Company Aggregate Debts|Company Total Debt Obligations xiliotx.com XLO|Company Total Debt Renovaro|Aggregate Debt Obligations Mural Oncology PLC MURA|KAPA: Company Aggregate Debts|OKUR: Company Total Debt|Company Debts GDTC|CRIS (Curis) - Company Cumulative Debt|APLM - Company Debts|Aggregate Debt Obligations THAR|ADVB - Company Debts|Company Aggregate Indebtedness GNPX (Genprex Inc.)|CLDI: Company Debts|sunshinebiopharma.com - Company Cumulative Debt|Company Debts Xenetic Bio (XBIO)|SLRX - Aggregate Debt Obligations|PPBT: Company Aggregate Debts|Company Aggregate Debts American Oncology Network, Inc.|BeOne Medicines (BGNE) - Company Total Debt|Company Cumulative Indebtedness Checkpoint Therapeutics Inc|ELEV (Elevation Oncology) - Company Aggregate Debts|Company Total Debt Obligations ICAD (icadmed.com)|IKNA: Company Debts|Notable Labs Ltd - Company Cumulative Debt|Viracta (VIRX) - Company Debts|MOR - Company Aggregate Debt|NAYA (NAYA Biosciences) - Company Aggregate Debts|Company Total Debt ascentage.com